Journal
SEMINARS IN CANCER BIOLOGY
Volume 74, Issue -, Pages 62-78Publisher
ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
DOI: 10.1016/j.semcancer.2021.02.010
Keywords
Extracellular vesicles; Anti-cancer therapy; Engineered EVs; Drug delivery; Nanomedicine
Categories
Funding
- National University of Singapore [NUHSRO/2019/076/STARTUP/02]
- Singapore Ministry of Education [NUHSRO/2020/108/T1/Seed-Mar/04]
- National Science Foundation of China [81972865]
- Shenzhen Innovation and Technology Fund [JCYJ20180507181636165]
- Hong Kong Innovation and Tech-nology Commission [ITS/201/18]
Ask authors/readers for more resources
EVs, as bio-derived drug delivery vectors, provide a breakthrough in cancer therapy due to their natural origin and role in intercellular communication. Engineered EVs, with surface functionalization and drug encapsulation, can enhance drug loading, stealth properties, and tumor targeting capabilities.
Cancer is a disease that evolves continuously with unpredictable outcomes. Although conventional chemotherapy can display significant antitumor effects, the lack of specificity and poor bioavailability remain major concerns in cancer therapy. Moreover, with the advent of novel anti-cancer gene therapies, there is an urgent need for drug delivery vectors capable of bypassing cellular barriers and efficiently transferring therapeutic cargo to recipient cells. A number of drug delivery systems have been proposed to overcome these limitations, but their successful clinical translation has been hampered by the onset of unexpected side effects and associated toxicities. The application of extracellular vesicles (EVs), a class of naturally released, cell-derived particles, as drug delivery vectors presents a breakthrough in nanomedicine, taking into account their biocompatibility and natural role in intercellular communication. Combining the advantageous intrinsic properties of EVs with surface functionalization and the encapsulation of drugs allows for a new class of engineered EVs that serve as effective therapeutic carriers. Here, we describe the various successful approaches involving the application of engineered EVs as bio-derived drug delivery vectors in cancer therapy. The latest and most effective strategies of engineering EVs to improve drug loading, stealth properties and tumour targeting capabilities of EVs are debated. Finally, current obstacles and future perspectives of smart engineered EVs are discussed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available